Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial
Summary Background Aromatase inhibitors effectively prevent breast cancer recurrence and development of new contralateral tumours in postmenopausal women. We assessed the efficacy and safety of the aromatase inhibitor anastrozole for prevention of breast cancer in postmenopausal women who are at hig...
Gespeichert in:
| Veröffentlicht in: | The Lancet (British edition) 2014-03, Vol.383 (9922), p.1041-1048 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1048 |
|---|---|
| container_issue | 9922 |
| container_start_page | 1041 |
| container_title | The Lancet (British edition) |
| container_volume | 383 |
| creator | Cuzick, Jack, Prof Sestak, Ivana, PhD Forbes, John F, Prof Dowsett, Mitch, Prof Knox, Jill, MSc Cawthorn, Simon, MD Saunders, Christobel, Prof Roche, Nicola, MD Mansel, Robert E, Prof von Minckwitz, Gunter, MD Bonanni, Bernardo, MD Palva, Tiina, MD Howell, Anthony, Prof |
| description | Summary Background Aromatase inhibitors effectively prevent breast cancer recurrence and development of new contralateral tumours in postmenopausal women. We assessed the efficacy and safety of the aromatase inhibitor anastrozole for prevention of breast cancer in postmenopausal women who are at high risk of the disease. Methods Between Feb 2, 2003, and Jan 31, 2012, we recruited postmenopausal women aged 40–70 years from 18 countries into an international, double-blind, randomised placebo-controlled trial. To be eligible, women had to be at increased risk of breast cancer (judged on the basis of specific criteria). Eligible women were randomly assigned (1:1) by central computer allocation to receive 1 mg oral anastrozole or matching placebo every day for 5 years. Randomisation was stratified by country and was done with blocks (size six, eight, or ten). All trial personnel, participants, and clinicians were masked to treatment allocation; only the trial statistician was unmasked. The primary endpoint was histologically confirmed breast cancer (invasive cancers or non-invasive ductal carcinoma in situ). Analyses were done by intention to treat. This trial is registered, number ISRCTN31488319. Findings 1920 women were randomly assigned to receive anastrozole and 1944 to placebo. After a median follow-up of 5·0 years (IQR 3·0–7·1), 40 women in the anastrozole group (2%) and 85 in the placebo group (4%) had developed breast cancer (hazard ratio 0·47, 95% CI 0·32–0·68, p |
| doi_str_mv | 10.1016/S0140-6736(13)62292-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1516744412</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0140673613622928</els_id><sourcerecordid>1516744412</sourcerecordid><originalsourceid>FETCH-LOGICAL-c554t-40af7618d116f203a03b00bdbe2627a51893db890d966559db237750a2f515e73</originalsourceid><addsrcrecordid>eNqNkd1qFDEcxQdR7Fp9BCUgwhY6mu_MeCHU4sdAwYsqeBcyM_-xabPJNJmp1GfxYc3sri145VVI8juHwzlF8Zzg1wQT-eYcE45LqZhcE3YkKa1pWT0oVoQrXgquvj8sVnfIQfEkpUuMMZdYPC4OKGeMYVyvit8n3qQphl_BARpCRGOEG_CTDR6FAbUR8jfqjO8gIuvRhf1xUUabrtAY0rQBH0YzJ-PQz5AvaN28b87Lpjl6i4zP_ATRm8XMuGPUh7l1ULbO-v4YReP7sLEJejQ600Ebyi74HMW5_DRFa9zT4tFgXIJn-_Ow-Pbxw9fTz-XZl0_N6clZ2QnBp5JjMyhJqp4QOVDMDGYtxm3fApVUGUGqmvVtVeO-llKIum8pU0pgQwdBBCh2WKx3vmMM1zOkSedcHThnPIQ5aSKIVJxzQv8Hzb0yInhGX_6DXoY51-EWCteY56lEpsSO6mJIKcKgx2g3Jt5qgvWytN4urZcZNWF6u7Susu7F3n1uN9Dfqf5Om4FXe8Ckzrgh993ZdM9VVNRKLkbvdhzkhm8sRN3lgWyWXMEtpPvMOlGNd2mWMIRto1TsD6O9xYc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1509041475</pqid></control><display><type>article</type><title>Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Cuzick, Jack, Prof ; Sestak, Ivana, PhD ; Forbes, John F, Prof ; Dowsett, Mitch, Prof ; Knox, Jill, MSc ; Cawthorn, Simon, MD ; Saunders, Christobel, Prof ; Roche, Nicola, MD ; Mansel, Robert E, Prof ; von Minckwitz, Gunter, MD ; Bonanni, Bernardo, MD ; Palva, Tiina, MD ; Howell, Anthony, Prof</creator><creatorcontrib>Cuzick, Jack, Prof ; Sestak, Ivana, PhD ; Forbes, John F, Prof ; Dowsett, Mitch, Prof ; Knox, Jill, MSc ; Cawthorn, Simon, MD ; Saunders, Christobel, Prof ; Roche, Nicola, MD ; Mansel, Robert E, Prof ; von Minckwitz, Gunter, MD ; Bonanni, Bernardo, MD ; Palva, Tiina, MD ; Howell, Anthony, Prof ; IBIS-II investigators</creatorcontrib><description>Summary Background Aromatase inhibitors effectively prevent breast cancer recurrence and development of new contralateral tumours in postmenopausal women. We assessed the efficacy and safety of the aromatase inhibitor anastrozole for prevention of breast cancer in postmenopausal women who are at high risk of the disease. Methods Between Feb 2, 2003, and Jan 31, 2012, we recruited postmenopausal women aged 40–70 years from 18 countries into an international, double-blind, randomised placebo-controlled trial. To be eligible, women had to be at increased risk of breast cancer (judged on the basis of specific criteria). Eligible women were randomly assigned (1:1) by central computer allocation to receive 1 mg oral anastrozole or matching placebo every day for 5 years. Randomisation was stratified by country and was done with blocks (size six, eight, or ten). All trial personnel, participants, and clinicians were masked to treatment allocation; only the trial statistician was unmasked. The primary endpoint was histologically confirmed breast cancer (invasive cancers or non-invasive ductal carcinoma in situ). Analyses were done by intention to treat. This trial is registered, number ISRCTN31488319. Findings 1920 women were randomly assigned to receive anastrozole and 1944 to placebo. After a median follow-up of 5·0 years (IQR 3·0–7·1), 40 women in the anastrozole group (2%) and 85 in the placebo group (4%) had developed breast cancer (hazard ratio 0·47, 95% CI 0·32–0·68, p<0·0001). The predicted cumulative incidence of all breast cancers after 7 years was 5·6% in the placebo group and 2·8% in the anastrozole group. 18 deaths were reported in the anastrozole group and 17 in the placebo group, and no specific causes were more common in one group than the other (p=0·836). Interpretation Anastrozole effectively reduces incidence of breast cancer in high-risk postmenopausal women. This finding, along with the fact that most of the side-effects associated with oestrogen deprivation were not attributable to treatment, provides support for the use of anastrozole in postmenopausal women at high risk of breast cancer. Funding Cancer Research UK, the National Health and Medical Research Council Australia, Sanofi-Aventis, and AstraZeneca.</description><identifier>ISSN: 0140-6736</identifier><identifier>EISSN: 1474-547X</identifier><identifier>DOI: 10.1016/S0140-6736(13)62292-8</identifier><identifier>PMID: 24333009</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>Kidlington: Elsevier</publisher><subject>Adult ; Aged ; Anastrozole ; Antineoplastic Agents, Hormonal - therapeutic use ; Aromatase Inhibitors - therapeutic use ; Biological and medical sciences ; Bone density ; Breast cancer ; Breast Neoplasms - prevention & control ; Carcinoma, Ductal, Breast - prevention & control ; Carcinoma, Intraductal, Noninfiltrating - prevention & control ; Carcinoma, Lobular - prevention & control ; Double-Blind Method ; Female ; General aspects ; Gynecology. Andrology. Obstetrics ; Hormone replacement therapy ; Humans ; Internal Medicine ; Longitudinal Studies ; Mammary gland diseases ; Mammography ; Medical research ; Medical sciences ; Middle Aged ; Nitriles - therapeutic use ; Postmenopause ; Prevention ; Prevention and actions ; Proportional Hazards Models ; Public health. Hygiene ; Public health. Hygiene-occupational medicine ; Risk Factors ; Treatment Outcome ; Triazoles - therapeutic use ; Tumors ; Womens health</subject><ispartof>The Lancet (British edition), 2014-03, Vol.383 (9922), p.1041-1048</ispartof><rights>Cuzick et al. Open Access article distributed under the terms of CC BY</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2014 Cuzick et al. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Mar 22, 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c554t-40af7618d116f203a03b00bdbe2627a51893db890d966559db237750a2f515e73</citedby><cites>FETCH-LOGICAL-c554t-40af7618d116f203a03b00bdbe2627a51893db890d966559db237750a2f515e73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28259768$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24333009$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cuzick, Jack, Prof</creatorcontrib><creatorcontrib>Sestak, Ivana, PhD</creatorcontrib><creatorcontrib>Forbes, John F, Prof</creatorcontrib><creatorcontrib>Dowsett, Mitch, Prof</creatorcontrib><creatorcontrib>Knox, Jill, MSc</creatorcontrib><creatorcontrib>Cawthorn, Simon, MD</creatorcontrib><creatorcontrib>Saunders, Christobel, Prof</creatorcontrib><creatorcontrib>Roche, Nicola, MD</creatorcontrib><creatorcontrib>Mansel, Robert E, Prof</creatorcontrib><creatorcontrib>von Minckwitz, Gunter, MD</creatorcontrib><creatorcontrib>Bonanni, Bernardo, MD</creatorcontrib><creatorcontrib>Palva, Tiina, MD</creatorcontrib><creatorcontrib>Howell, Anthony, Prof</creatorcontrib><creatorcontrib>IBIS-II investigators</creatorcontrib><title>Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial</title><title>The Lancet (British edition)</title><addtitle>Lancet</addtitle><description>Summary Background Aromatase inhibitors effectively prevent breast cancer recurrence and development of new contralateral tumours in postmenopausal women. We assessed the efficacy and safety of the aromatase inhibitor anastrozole for prevention of breast cancer in postmenopausal women who are at high risk of the disease. Methods Between Feb 2, 2003, and Jan 31, 2012, we recruited postmenopausal women aged 40–70 years from 18 countries into an international, double-blind, randomised placebo-controlled trial. To be eligible, women had to be at increased risk of breast cancer (judged on the basis of specific criteria). Eligible women were randomly assigned (1:1) by central computer allocation to receive 1 mg oral anastrozole or matching placebo every day for 5 years. Randomisation was stratified by country and was done with blocks (size six, eight, or ten). All trial personnel, participants, and clinicians were masked to treatment allocation; only the trial statistician was unmasked. The primary endpoint was histologically confirmed breast cancer (invasive cancers or non-invasive ductal carcinoma in situ). Analyses were done by intention to treat. This trial is registered, number ISRCTN31488319. Findings 1920 women were randomly assigned to receive anastrozole and 1944 to placebo. After a median follow-up of 5·0 years (IQR 3·0–7·1), 40 women in the anastrozole group (2%) and 85 in the placebo group (4%) had developed breast cancer (hazard ratio 0·47, 95% CI 0·32–0·68, p<0·0001). The predicted cumulative incidence of all breast cancers after 7 years was 5·6% in the placebo group and 2·8% in the anastrozole group. 18 deaths were reported in the anastrozole group and 17 in the placebo group, and no specific causes were more common in one group than the other (p=0·836). Interpretation Anastrozole effectively reduces incidence of breast cancer in high-risk postmenopausal women. This finding, along with the fact that most of the side-effects associated with oestrogen deprivation were not attributable to treatment, provides support for the use of anastrozole in postmenopausal women at high risk of breast cancer. Funding Cancer Research UK, the National Health and Medical Research Council Australia, Sanofi-Aventis, and AstraZeneca.</description><subject>Adult</subject><subject>Aged</subject><subject>Anastrozole</subject><subject>Antineoplastic Agents, Hormonal - therapeutic use</subject><subject>Aromatase Inhibitors - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Bone density</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - prevention & control</subject><subject>Carcinoma, Ductal, Breast - prevention & control</subject><subject>Carcinoma, Intraductal, Noninfiltrating - prevention & control</subject><subject>Carcinoma, Lobular - prevention & control</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>General aspects</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Hormone replacement therapy</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Longitudinal Studies</subject><subject>Mammary gland diseases</subject><subject>Mammography</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nitriles - therapeutic use</subject><subject>Postmenopause</subject><subject>Prevention</subject><subject>Prevention and actions</subject><subject>Proportional Hazards Models</subject><subject>Public health. Hygiene</subject><subject>Public health. Hygiene-occupational medicine</subject><subject>Risk Factors</subject><subject>Treatment Outcome</subject><subject>Triazoles - therapeutic use</subject><subject>Tumors</subject><subject>Womens health</subject><issn>0140-6736</issn><issn>1474-547X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNkd1qFDEcxQdR7Fp9BCUgwhY6mu_MeCHU4sdAwYsqeBcyM_-xabPJNJmp1GfxYc3sri145VVI8juHwzlF8Zzg1wQT-eYcE45LqZhcE3YkKa1pWT0oVoQrXgquvj8sVnfIQfEkpUuMMZdYPC4OKGeMYVyvit8n3qQphl_BARpCRGOEG_CTDR6FAbUR8jfqjO8gIuvRhf1xUUabrtAY0rQBH0YzJ-PQz5AvaN28b87Lpjl6i4zP_ATRm8XMuGPUh7l1ULbO-v4YReP7sLEJejQ600Ebyi74HMW5_DRFa9zT4tFgXIJn-_Ow-Pbxw9fTz-XZl0_N6clZ2QnBp5JjMyhJqp4QOVDMDGYtxm3fApVUGUGqmvVtVeO-llKIum8pU0pgQwdBBCh2WKx3vmMM1zOkSedcHThnPIQ5aSKIVJxzQv8Hzb0yInhGX_6DXoY51-EWCteY56lEpsSO6mJIKcKgx2g3Jt5qgvWytN4urZcZNWF6u7Susu7F3n1uN9Dfqf5Om4FXe8Ckzrgh993ZdM9VVNRKLkbvdhzkhm8sRN3lgWyWXMEtpPvMOlGNd2mWMIRto1TsD6O9xYc</recordid><startdate>20140322</startdate><enddate>20140322</enddate><creator>Cuzick, Jack, Prof</creator><creator>Sestak, Ivana, PhD</creator><creator>Forbes, John F, Prof</creator><creator>Dowsett, Mitch, Prof</creator><creator>Knox, Jill, MSc</creator><creator>Cawthorn, Simon, MD</creator><creator>Saunders, Christobel, Prof</creator><creator>Roche, Nicola, MD</creator><creator>Mansel, Robert E, Prof</creator><creator>von Minckwitz, Gunter, MD</creator><creator>Bonanni, Bernardo, MD</creator><creator>Palva, Tiina, MD</creator><creator>Howell, Anthony, Prof</creator><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TT</scope><scope>0TZ</scope><scope>0U~</scope><scope>3V.</scope><scope>7QL</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88C</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>KB~</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope><scope>7U1</scope><scope>7U2</scope></search><sort><creationdate>20140322</creationdate><title>Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial</title><author>Cuzick, Jack, Prof ; Sestak, Ivana, PhD ; Forbes, John F, Prof ; Dowsett, Mitch, Prof ; Knox, Jill, MSc ; Cawthorn, Simon, MD ; Saunders, Christobel, Prof ; Roche, Nicola, MD ; Mansel, Robert E, Prof ; von Minckwitz, Gunter, MD ; Bonanni, Bernardo, MD ; Palva, Tiina, MD ; Howell, Anthony, Prof</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c554t-40af7618d116f203a03b00bdbe2627a51893db890d966559db237750a2f515e73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anastrozole</topic><topic>Antineoplastic Agents, Hormonal - therapeutic use</topic><topic>Aromatase Inhibitors - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Bone density</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - prevention & control</topic><topic>Carcinoma, Ductal, Breast - prevention & control</topic><topic>Carcinoma, Intraductal, Noninfiltrating - prevention & control</topic><topic>Carcinoma, Lobular - prevention & control</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>General aspects</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Hormone replacement therapy</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Longitudinal Studies</topic><topic>Mammary gland diseases</topic><topic>Mammography</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nitriles - therapeutic use</topic><topic>Postmenopause</topic><topic>Prevention</topic><topic>Prevention and actions</topic><topic>Proportional Hazards Models</topic><topic>Public health. Hygiene</topic><topic>Public health. Hygiene-occupational medicine</topic><topic>Risk Factors</topic><topic>Treatment Outcome</topic><topic>Triazoles - therapeutic use</topic><topic>Tumors</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cuzick, Jack, Prof</creatorcontrib><creatorcontrib>Sestak, Ivana, PhD</creatorcontrib><creatorcontrib>Forbes, John F, Prof</creatorcontrib><creatorcontrib>Dowsett, Mitch, Prof</creatorcontrib><creatorcontrib>Knox, Jill, MSc</creatorcontrib><creatorcontrib>Cawthorn, Simon, MD</creatorcontrib><creatorcontrib>Saunders, Christobel, Prof</creatorcontrib><creatorcontrib>Roche, Nicola, MD</creatorcontrib><creatorcontrib>Mansel, Robert E, Prof</creatorcontrib><creatorcontrib>von Minckwitz, Gunter, MD</creatorcontrib><creatorcontrib>Bonanni, Bernardo, MD</creatorcontrib><creatorcontrib>Palva, Tiina, MD</creatorcontrib><creatorcontrib>Howell, Anthony, Prof</creatorcontrib><creatorcontrib>IBIS-II investigators</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>News PRO</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Global News & ABI/Inform Professional</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>British Nursing Index</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Newsstand Professional</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><collection>Risk Abstracts</collection><collection>Safety Science and Risk</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cuzick, Jack, Prof</au><au>Sestak, Ivana, PhD</au><au>Forbes, John F, Prof</au><au>Dowsett, Mitch, Prof</au><au>Knox, Jill, MSc</au><au>Cawthorn, Simon, MD</au><au>Saunders, Christobel, Prof</au><au>Roche, Nicola, MD</au><au>Mansel, Robert E, Prof</au><au>von Minckwitz, Gunter, MD</au><au>Bonanni, Bernardo, MD</au><au>Palva, Tiina, MD</au><au>Howell, Anthony, Prof</au><aucorp>IBIS-II investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial</atitle><jtitle>The Lancet (British edition)</jtitle><addtitle>Lancet</addtitle><date>2014-03-22</date><risdate>2014</risdate><volume>383</volume><issue>9922</issue><spage>1041</spage><epage>1048</epage><pages>1041-1048</pages><issn>0140-6736</issn><eissn>1474-547X</eissn><coden>LANCAO</coden><abstract>Summary Background Aromatase inhibitors effectively prevent breast cancer recurrence and development of new contralateral tumours in postmenopausal women. We assessed the efficacy and safety of the aromatase inhibitor anastrozole for prevention of breast cancer in postmenopausal women who are at high risk of the disease. Methods Between Feb 2, 2003, and Jan 31, 2012, we recruited postmenopausal women aged 40–70 years from 18 countries into an international, double-blind, randomised placebo-controlled trial. To be eligible, women had to be at increased risk of breast cancer (judged on the basis of specific criteria). Eligible women were randomly assigned (1:1) by central computer allocation to receive 1 mg oral anastrozole or matching placebo every day for 5 years. Randomisation was stratified by country and was done with blocks (size six, eight, or ten). All trial personnel, participants, and clinicians were masked to treatment allocation; only the trial statistician was unmasked. The primary endpoint was histologically confirmed breast cancer (invasive cancers or non-invasive ductal carcinoma in situ). Analyses were done by intention to treat. This trial is registered, number ISRCTN31488319. Findings 1920 women were randomly assigned to receive anastrozole and 1944 to placebo. After a median follow-up of 5·0 years (IQR 3·0–7·1), 40 women in the anastrozole group (2%) and 85 in the placebo group (4%) had developed breast cancer (hazard ratio 0·47, 95% CI 0·32–0·68, p<0·0001). The predicted cumulative incidence of all breast cancers after 7 years was 5·6% in the placebo group and 2·8% in the anastrozole group. 18 deaths were reported in the anastrozole group and 17 in the placebo group, and no specific causes were more common in one group than the other (p=0·836). Interpretation Anastrozole effectively reduces incidence of breast cancer in high-risk postmenopausal women. This finding, along with the fact that most of the side-effects associated with oestrogen deprivation were not attributable to treatment, provides support for the use of anastrozole in postmenopausal women at high risk of breast cancer. Funding Cancer Research UK, the National Health and Medical Research Council Australia, Sanofi-Aventis, and AstraZeneca.</abstract><cop>Kidlington</cop><pub>Elsevier</pub><pmid>24333009</pmid><doi>10.1016/S0140-6736(13)62292-8</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0140-6736 |
| ispartof | The Lancet (British edition), 2014-03, Vol.383 (9922), p.1041-1048 |
| issn | 0140-6736 1474-547X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1516744412 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Aged Anastrozole Antineoplastic Agents, Hormonal - therapeutic use Aromatase Inhibitors - therapeutic use Biological and medical sciences Bone density Breast cancer Breast Neoplasms - prevention & control Carcinoma, Ductal, Breast - prevention & control Carcinoma, Intraductal, Noninfiltrating - prevention & control Carcinoma, Lobular - prevention & control Double-Blind Method Female General aspects Gynecology. Andrology. Obstetrics Hormone replacement therapy Humans Internal Medicine Longitudinal Studies Mammary gland diseases Mammography Medical research Medical sciences Middle Aged Nitriles - therapeutic use Postmenopause Prevention Prevention and actions Proportional Hazards Models Public health. Hygiene Public health. Hygiene-occupational medicine Risk Factors Treatment Outcome Triazoles - therapeutic use Tumors Womens health |
| title | Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T16%3A50%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anastrozole%20for%20prevention%20of%20breast%20cancer%20in%20high-risk%20postmenopausal%20women%20(IBIS-II):%20an%20international,%20double-blind,%20randomised%20placebo-controlled%20trial&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=Cuzick,%20Jack,%20Prof&rft.aucorp=IBIS-II%20investigators&rft.date=2014-03-22&rft.volume=383&rft.issue=9922&rft.spage=1041&rft.epage=1048&rft.pages=1041-1048&rft.issn=0140-6736&rft.eissn=1474-547X&rft.coden=LANCAO&rft_id=info:doi/10.1016/S0140-6736(13)62292-8&rft_dat=%3Cproquest_cross%3E1516744412%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1509041475&rft_id=info:pmid/24333009&rft_els_id=1_s2_0_S0140673613622928&rfr_iscdi=true |